Author: Ravi Shankar

MIAMI BEACH, FL, Sept. 23, 2026 (GLOBE NEWSWIRE) — Cuentas, Inc. (OTCQB: CUEN) today announced a strategic Power-as-a-Service (PaaS) and Colocation Services Agreement with Power Upp USA, Inc. (“PWRU”) for a proposed West Texas Bitcoin mining operation designed to utilize electricity generated from methane and associated gas produced in connection with oil-field operations.

The initiative expands Cuentas’ participation in the Bitcoin ecosystem by combining energy recovery, onsite power generation, Bitcoin mining and the Company’s Bitcoin Mobile wireless service, creating a connection between Cuentas’ telecommunications customers and its digital-asset infrastructure.

Turning Stranded Energy into Productive Power

The proposed project is designed to capture and utilize methane and associated gas at or near the oil-production site, where transportation of the gas or access to conventional grid power may be limited. By generating electricity onsite, the project is intended to reduce reliance on conventional utility power while putting an underutilized energy resource to productive use.

Federal environmental regulations, including the EPA’s New Source Performance Standards for the oil and natural gas sector, address methane emissions and associated gas from covered oil and gas operations. Cuentas believes that projects that recover and beneficially use associated gas can provide both economic and environmental value, subject to applicable regulatory requirements and project-specific circumstances.

Cuentas does not characterize the project as zero-emission. Rather, its potential environmental benefit is based on the productive utilization of associated gas that might otherwise have limited economic value or require alternative handling under applicable regulations.

Revenue, Competitive Energy Economics and Local Benefits

Phase 1 of the project should provide Cuentas with approximately 1.5 BTC (Bitcoins) per month in revenue. The current average BTC price over $86,000 should yield revenue of approx. $130,000 per month.

The PaaS Colocation project will also provide lower-cost power than many conventional Bitcoin mining operations that depend upon higher-cost grid electricity. Combining these financial benefits should product monthly profit of up to $43,000. Cuentas is planning to use these BTC profits to subsidize and/or reward its customers with enhanced mobile services, cyber-security & VPN.

Additionally, the public should welcome this ecologically beneficial project as it will create jobs, significantly reduce the gas burned off at the oilfields and no public utility will be used. This project provides a win-win solution for the oilfield producers, the local economy and does not cause public complaints as do so many data center projects currently in the news.

The proposed deployment in Phase 1 contemplates 1 containerized mining unit, approximately 2.4 megawatts of contracted power capacity and approximately 420 operational ASIC miners, plus 12 spares. Phase 2 is scheduled for up to up to 10 containerized mining units, approximately 24 megawatts of contracted power capacity and approximately 4,200 operational ASIC miners with 120 spares when fully deployed. At current Bitcoin prices, Phase 2 should yield revenue of approx. $1.3 Million per month with profit of approx. $430,000. Deployment is expected to occur in stages, allowing Cuentas to evaluate actual operating performance and economics as the project progresses.

“We believe this project represents an exciting opportunity to connect energy recovery, digital infrastructure and our telecommunications strategy,” said Shalom Arik Maimon, CEO of Cuentas. “Our objective is to utilize an otherwise stranded energy resource to generate electricity onsite while building a potentially efficient Bitcoin mining platform that can contribute to recurring revenue and support our broader digital-asset strategy.”

“We are pleased to partner with Cuentas as it advances its Digital-asset strategy,” said Matt Inan, Chief Executive Officer of Power Upp USA, Inc. “This agreement reflects the value of pairing dependable, scalable power infrastructure with flexible colocation services for high-performance compute and digital-asset applications. We look forward to supporting Cuentas with a solution designed to help it deploy efficiently and scale in line with its operational requirements.”

Bitcoin Mobile: Connecting Wireless Service with Bitcoin Rewards

Cuentas is developing Bitcoin Mobile, a next-generation mobile service designed to combine high-quality nationwide wireless connectivity with subsidies and/or Bitcoin rewards, sourced from its BTC profits.

“Bitcoin Mobile is aiming to become a worldwide company that provides both US e-SIMs and MULTI-IMSI e-SIMs (local operations in foreign countries) designed to give consumers a practical way to receive indirect benefits from the Bitcoin economy while receiving the high-quality wireless service they already need,” added Maimon. “Combined with our planned Bitcoin mining activities, we believe Cuentas can participate across multiple levels of the Bitcoin ecosystem—from telecommunications and consumer rewards to energy-efficient digital-asset infrastructure.”

Staged Development

Cuentas intends to evaluate actual power availability, generator performance, mining output, operating costs and revenue generation during staged deployment before proceeding with subsequent phases.

The Company cautions investors that the contemplated mining project does not guarantee future Bitcoin production or profitability. Actual results will depend on Bitcoin prices, network difficulty, ASIC efficiency, power availability, methane supply, generator performance, operating expenses, regulatory requirements and other factors.

About Cuentas, Inc.

Cuentas, Inc. (OTCQB: CUEN) is developing financial technology, telecommunications and digital infrastructure solutions designed to create technology-enabled services and new sources of recurring revenue. Through its majority-owned subsidiary, World Mobile LLC, Cuentas is expanding its participation in telecommunications, Bitcoin mining and blockchain-related infrastructure. Cuentas believes these complementary businesses have the potential to create new consumer services and additional sources of shareholder value.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of U.S. federal securities laws. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company’s plans and expectations relating to its SEC reporting status, any potential listing on a major U.S. exchange  or relisting on the Nasdaq Capital Market, business strategy, future operations, and prospects.

Forward-looking statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by any forward-looking statement. Important factors that could cause actual results to differ materially include, among others, the Company’s ability to continue to meet SEC reporting obligations, , to obtain necessary approvals, to fund its operations, and to execute its business strategy, as well as other risks described in the Company’s filings with the SEC.

Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Shalom Arik Maimon – CEO
Cuentas, Inc.
235 Lincoln Road, Suite 210
Miami Beach, FL 33139

info@cuentas.com
www.cuentas.com

– Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders –

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has initiated the process to market and sell the remaining assets associated with the Company’s former biosimilars business (the “Legacy BioSim Assets”). The Company has retained Oppenheimer & Co. Inc. (“Oppenheimer”) to serve as its financial advisor in connection with the sale. Parties interested in the opportunity should direct inquiries to the Oppenheimer contacts listed below.

“We are pleased to be working with a bank of Oppenheimer’s caliber to market our legacy biosimilars assets,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “We are confident that this will result in a robust process with global reach to solicit interest and bids for this attractive asset package, for the benefit of our shareholders.”

As previously announced on August 17, 2026, the Company declared a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed pro rata to stockholders of record of the Company’s common stock as of September 30, 2026 (the “Record Date”), with distribution occurring on October 7, 2026. CVR holders are entitled to receive their pro rata share of any net cash proceeds, and the net cash value of any other consideration, actually received by the Company from third parties in connection with the sale of the Legacy BioSim Assets or as licensing fees under any licensing agreement covering the Legacy BioSim Assets.

The Legacy BioSim Assets include:

        • Patents and other intellectual property
        • Royalties under an existing license agreement
        • Cell lines
        • Related materials, including laboratory notebooks, regulatory filings, and product samples

To be eligible to receive the CVRs, an investor must be a stockholder of record of the Company’s common stock as of the Record Date. Investors should contact their brokers with any questions regarding their holder status as of the Record Date.

Further Information

The terms of the CVRs are set forth in, and the CVRs are governed by, the Contingent Value Rights Agreement by and between the Company and Equiniti Trust Company, LLC, as rights agent (the “CVR Agreement”). The Company’s stockholders are also encouraged to review the FAQ concerning the CVRs. The CVR Agreement and the FAQ were included as exhibits to the Form 8-K that the Company filed with the SEC on August 17, 2026, and are available on the Investors & Media – Shareholder Services section of the Company’s website.

Stockholders who hold their shares through a broker should note that the crediting of CVRs may be subject to the practices and procedures of such intermediary. In certain circumstances, including where shares are rehypothecated or loaned out, different mechanics may apply, and it is possible that an investor will not receive the CVRs if its shares are rehypothecated or loaned out as of the Record Date. Stockholders are encouraged to contact their broker directly for confirmation and for additional information regarding the timing and manner in which the CVRs will be reflected in their accounts.

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma while advancing the development of its two pipeline candidates in combination with LOQTORZI, and additionally through strategic partnerships. The Company has global rights to both clinical stage-candidates and plans to execute ex-U.S. licensing deals as the clinical data supports such transactions.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated distribution of the CVRs, the expected record date and distribution date, the proposed process to market and sell the Legacy BioSim Assets, the timing and outcome of that process, and the value, timing, and amount, if any, of proceeds that may become distributable to CVR holders. These statements are based on Coherus’ current expectations and involve substantial risks and uncertainties that could cause actual results to differ materially, including the risk that no sale or licensing transaction involving the Legacy BioSim Assets is consummated, that any transaction that is consummated is on terms less favorable than anticipated, and that CVR holders may receive little or no payment under the CVRs. These and other risks are described in Coherus’ filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Coherus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Oppenheimer Contact Information:
Stefan Loren, Ph.D.
Managing Director — Oppenheimer & Co. Inc.
Stefan.Loren@opco.com

Arif Sheikh
Managing Director — Oppenheimer & Co. Inc.
Arif.Sheikh@opco.com

Coherus Contact Information:
For Investors & Media:
Carrie Graham
Vice President, Investor Relations and Advocacy
IR@coherus.com

LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced dial-in details for its previously announced investor update call to be held on September 24, 2026, at 4:15 p.m. Eastern Time.

Investor Update Call Details

Date: September 24, 2026
Time: 4:15 p.m. Eastern Time
Live Call: 1-833-309-3473 (U.S. Toll Free) or 1-785-838-9251 (International)
Conference ID: NEXGEL

For interested individuals unable to join the conference call, a replay will be available through October 1, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following access code to access the replay of the call: 11162643.

The call will provide investors with an update on the Company’s operational progress, commercialization initiatives, and other corporate matters.

About NEXGEL, INC.

NEXGEL, through its Bionx Surgical division, is a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience. Bionx has a strong offering of products including Biovance (human amniotic membrane allograft), Biovance 3L (tri-layer human amniotic membrane allograft), Interfyl (human connective tissue matrix), SilverSeal (antimicrobial hydrogel wound dressing), and an expansive opthalmic portfolio of placental derived ocular allografts (LUCENT, single layer, RADIANT, dual layer, and VIVID, triple layer). Additionally, NEXGEL is a provider of healthcare, beauty, and over the counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. In addition to the above, NEXGEL brands include Hexagels^®, Turfguard^®, Kenkoderm^® and Silly George^®. NEXGEL also has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, statements regarding the timing, content, and conduct of the anticipated investor update call. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com

Not for distribution to United States newswire services or for dissemination in the United States. Not an offer of securities for sale in the United States

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Fredonia Mining Inc. (“Fredonia” or the “Company”) (TSXV: FRED) is pleased to announce that it has closed its previously announced “bought deal” private placement, pursuant to which it has issued an aggregate of 17,692,400 common shares of the Company (the “Offered Shares”) at a price of C$0.65 per Offered Share for aggregate gross proceeds of C$11,500,060, which includes the full exercise of the underwriters’ option (collectively, the “Offering”).

The Company intends to use the net proceeds from the Offering for the exploration and advancement of the Company’s El Dorado Monserrat Project in Santa Cruz province, Argentina, and for general corporate and working capital purposes, all as further described in the offering document relating to the Offering.

The Offering was completed by a syndicate of underwriters led by ATB Cormark Capital Markets (the “Lead Underwriter”), as lead underwriter and sole bookrunner, and which included Canaccord Genuity Corp. (together with the Lead Underwriter, the “Underwriters” and each individually, an “Underwriter”). In consideration for the services provided by the Underwriters in connection with the Offering, the Company paid the Underwriters a cash commission equal to 6.0% of the gross proceeds of the Offering, other than in respect of gross proceeds from sales to purchasers on the President’s List, for which a cash commission equal to 3.0% of the gross proceeds was payable.

Directors and executive officers of the Company subscribed for a total of 500,000 Offered Shares in the Offering for aggregate gross proceeds of C$325,000. The participation of insiders in the Offering constitutes a “related party transaction”, within the meaning of the TSX Venture Exchange (the “Exchange”) Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(1)(b) of MI 61-101 in respect of the related party participation in the Offering, which will be described in further detail in a material change report to be filed in connection with the Offering that will be accessible under the Company’s profile on SEDAR+ at www.sedarplus.ca. The material change report relating to the Offering will be filed less than 21 days prior to the closing date of the Offering. The Company believes the shorter period was reasonable and necessary in the circumstances, as the typical lifecycle for a transaction of this nature is significantly less than 21 days and the Company desired to act on an available financing opportunity.

In accordance with National Instrument 45-106 Prospectus Exemptions (“NI 45-106”), the Offered Shares were issued to purchasers resident in certain provinces of Canada pursuant to the “listed issuer financing exemption” (the “Listed Issuer Financing Exemption”) under Part 5A.2 of NI 45-106, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The Offered Shares issued to purchasers resident in Canada pursuant to the Listed Issuer Financing Exemption are not subject to a four-month statutory hold period in Canada. The Offered Shares were also offered in the United States by way of private placement pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and in certain other jurisdictions outside of Canada and the United States on a private placement or equivalent basis, in each case in accordance with all applicable laws. The Offered Shares were issued to purchasers outside of Canada pursuant to an exemption from the prospectus requirements in Canada available under OSC Rule 72-503 – Distributions Outside Canada and, accordingly, the Offered Shares issued to purchasers outside of Canada are not subject to a four-month statutory hold period in Canada. The Offered Shares sold to officers and directors of the Company (as described above) are subject to a four-month hold period pursuant to the rules of the Exchange, expiring January 24, 2027.

The Offering remains subject to final approval of the Exchange.

The securities described herein have not been, and will not be, registered under the U.S. Securities Act, or any U.S. state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the “United States” or to “U.S. persons” (as such terms are defined in Regulation S under the U.S. Securities Act), absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with an exemption therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.‎

Update on Warrant Amendment Transaction

Pursuant to a news release dated December 17, 2025, the Company announced an intention to amend the exercise price of 4,818,932 outstanding warrants to purchase common shares at a price of $1.40 per common share (in the case of each of the price and amount, on an effective, “post-consolidation” basis) to $0.45 per common share. The reduction remained subject to warrantholder and Exchange approvals. As the Company has since the date of the announcement been able to complete financing activity at a higher price per share in order to fund its operations and work programs at the EDM Project, the Company announces it will withdraw its application and intention to proceed with the price reduction. The warrants will remain outstanding and be exercisable in accordance with their terms at a price of $1.40 per share until April 27, 2027.

About Fredonia

Fredonia holds gold and silver license areas totaling approximately 64,000 ha in the prolific Deseado Massif geological region in the Province of Santa Cruz, Argentina, including its flagship advanced EDM project (approximately 33,500 ha) located close to AngloGold Ashanti’s Cerro Vanguardia gold-silver mine (which produced approximately 180,000 ounces of gold during the twelve months ended June 30, 2026*), the El Águila project (approximately 9,100 ha), and the Hornia project (approximately 21,500 ha).

* Source: AngloGold Ashanti plc’s 2025 Form 20-F and Q2 2026 Earnings Release: Operating Statistics. The twelve-month production figure was calculated from the reported production of 179,000 ounces of gold in 2025, less 94,000 ounces produced during the six months ended June 30, 2025, plus 95,000 ounces produced during the six months ended June 30, 2026. Scientific and technical information concerning the Cerro Vanguardia mine has been obtained from publicly available disclosure by AngloGold Ashanti plc and has not been independently verified by the Company’s Qualified Person. Information concerning Cerro Vanguardia is not necessarily indicative of the mineralization, Mineral Resources, or Mineral Reserves on, or the economic potential of, the EDM Project.

For further information: Please visit the Company’s website at www.fredoniamanagement.com or contact: Estanislao Auriemma, Chief Executive Officer, Direct +54 91 149 980 623, Email: estanislao.auriemma@gmail.com.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. “Forward-looking information” includes, but is not limited to, statements with respect to activities, events or developments that the Company expects or anticipates will or may occur in the future, including, without limitation, the anticipated use of the net proceeds of the Offering; the anticipated receipt of all necessary approvals in respect of the Offering, and the intention to abandon the Company’s application to proceed with a reduction in price to outstanding warrants exercisable at an effective price of $1.40 per common share. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

In disclosing the forward-looking information in this release, Fredonia has applied certain factors and assumptions that are based on Fredonia’s current beliefs as well as assumptions made by and information currently available to Fredonia including, among other things, that the Company will use the net proceeds of the Offering as anticipated; and that the Company will receive all necessary approvals in respect of the Offering. Although Fredonia considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking information in this release is subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking information.

Readers are cautioned not to place undue reliance on forward-looking information. Fredonia does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by law.

The expanded partnership delivers a complete, behind-the-meter distributed compute solution for residential deployment at gigawatt scale, built into new home communities from the ground up

SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, and SPAN, the leader in intelligent home energy management, today announced a partnership expansion to accelerate AI compute capacity by combining home energy systems with distributed compute infrastructure. Under the partnership, Sunrun will provide home solar and battery storage to help power SPAN’s XFRA distributed data center solution, accelerating deployed compute capacity.

The partnership combines Sunrun’s home energy products, financing, and installation and service network with SPAN’s XFRA distributed compute node and orchestration capabilities to deliver a scalable, low-cost, low-latency compute solution that can be deployed faster than traditional data centers.

“This partnership expansion with SPAN puts customers first, ensuring that they directly benefit in multiple ways from their participation in this powerful distributed AI solution,” said Sunrun CEO Mary Powell. “By pairing home energy generation and storage with XFRA compute nodes, we are unlocking new economic value for our customers and for Sunrun, while also solving certain speed-to-power constraints that would otherwise limit AI deployment.”

Under the partnership, SPAN and Sunrun will partner with leading homebuilders and begin deployments in new construction residential communities in Texas and other specified markets, enabling distributed AI infrastructure to be built into communities from the ground up. Sunrun’s battery-plus-solar systems will maintain reliable electricity for both the homes and the XFRA compute nodes, while preventing the overloading of local distribution infrastructure—allowing SPAN to maximize node deployment.

“Teaming up with Sunrun solves one of the main bottlenecks for distributed AI compute: power generation and transmission constraints,” said Arch Rao, founder and CEO of SPAN. “We can now drastically increase our penetration of XFRA compute nodes by pairing them with Sunrun energy systems to deliver cost-effective AI compute capacity at unprecedented speed while also reducing compute cost for certain AI applications.”

At no cost to the builder or the homeowner, and without increasing the purchase price of the home, each host customer will receive a smart electrical panel paired with a multi-battery storage and solar system through a pre-paid lease. Customers will also receive whole-home backup power and ongoing compensation for hosting the XFRA compute node.

SPAN’s XFRA platform utilizes liquid-cooled NVIDIA GPUs that are managed through SPAN’s XFRA Secure Orchestration Layer, which intelligently schedules AI workloads based on latency requirements and real-time energy availability at each home.

In addition to providing capacity for the compute nodes and local power infrastructure, Sunrun will enroll the home batteries in its grid service programs, growing Sunrun’s market-leading distributed power plant fleet.

Together, Sunrun and SPAN represent the only end-to-end platform for residential AI compute, combining the nation’s largest residential energy platform with XFRA’s distributed compute network to bring distributed compute capacity online at the speed and scale the AI buildout demands.

About Sunrun
Sunrun Inc. (Nasdaq: RUN) is America’s largest provider of home battery storage, solar, and home-to-grid power plants. As the pioneer of home energy systems offered through a no-upfront-cost subscription model, Sunrun empowers customers nationwide with greater energy control, security, and independence. Sunrun supports the grid by providing on-demand dispatchable power that helps prevent blackouts and lowers energy costs. Learn more at www.sunrun.com.

About SPAN
SPAN is on a mission to enable a more efficient and affordable energy future. The company began by reinventing the electrical panel and continues to transform grid-edge energy infrastructure through combined hardware and software innovation. The SPAN product portfolio includes five smart electrical panel models, SPAN Edge (the intelligent service point), XFRA (the distributed data center), EV charging solutions, and the SPAN Home App. SPAN delivers energy management and advanced power controls that unlock greater grid utilization, benefiting homeowners, builders, utilities, and data center developers with lower costs and faster speed to power. For more information, go to www.span.io.

Sunrun Media Contact
Wyatt Semanek
Sr. Director, Corporate Communications
press@sunrun.com

SPAN Media Contact
press@span.io

Investor & Analyst Contact
Patrick Jobin
SVP, Deputy CFO & Investor Relations Officer
investors@sunrun.com

THIO-104 advances toward key 2027 interim survival analysis

CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for its ongoing pivotal Phase 3 THIO-104 clinical trial in non-small cell lung cancer (NSCLC).

Spain and Portugal represent important European markets for NSCLC, with an estimated 30,000 new cases annually across the two countries. Spain has a substantial lung cancer burden associated with historical tobacco exposure, with lung cancer incidence among women continuing to rise. In Portugal, NSCLC accounts for approximately 82% of lung cancer cases, the highest proportion reported among five European populations evaluated in a comparative study.

“Expanding THIO-104 into Spain and Portugal represents another important step in the execution of our pivotal Phase 3 program,” said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. “Clinical trial participation can provide patients with access to investigational therapies in markets where access to newly approved lung cancer treatments has historically lagged. By establishing THIO-104 sites in Spain and Portugal, we are broadening access to a potentially important new treatment option for patients with advanced NSCLC who have progressed following standard of care treatments.”

To date, THIO-104 has enrolled 65 NSCLC patients resistant to chemotherapy and checkpoint inhibitor treatments at 28 clinical sites in 6 European countries and 10 sites in Taiwan. Among the six European countries, sites in Hungary, Poland, and Turkey are actively enrolling and dosing patients from populations with the highest lung cancer incidence and mortality rates in Europe and globally.¹

MAIA targets 100 patients dosed in THIO-104 by year-end 2026 and expects to have sufficient survival data to conduct an interim data analysis in 2027.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

---

¹ Sources: Global Cancer Observatory (GLOBOCAN), European Cancer Information System (ECIS), World Cancer Research Fund

The LP Foundation Joins Rutgers University and Sirica Therapeutics in Omni One Neurodivergent Therapy Initiative

Pilot Will Evaluate AI-Driven, Movement-Based Therapy Across Multiple Real-World Care Settings

AUSTIN, Texas, Sept. 23, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced the expansion of its healthcare initiative focused on serving neurodivergent communities, adding The LP Foundation as a partner in the deployment of immersive educational and enrichment experiences using Virtuix’s Omni One platform.

The new partnership builds on Virtuix’s existing work with Rutgers University WINLAB and Sirica Therapeutics, marking the next stage of the Company’s effort to evaluate virtual reality, AI and natural full-body movement in therapeutic, educational, and enrichment applications for children with autism. Virtuix and its partners plan to begin a multi-site pilot program in January 2027.

Omni One systems will be deployed at The LP Foundation’s new enrichment center in New Jersey, alongside the systems already deployed at Sirica Therapeutics’ therapy center in the San Francisco Bay Area. Sirica Therapeutics has announced plans to establish approximately 100 autism treatment centers nationwide.

Virtuix believes autism therapy represents a potentially significant healthcare market for Omni One. There are approximately 12,000 Applied Behavior Analysis (“ABA”) therapy providers and centers across the United States, providing a large potential channel for movement-based immersive applications if the pilot program and subsequent development demonstrate clinical utility. Together, Sirica’s planned network of approximately 100 centers, The LP Foundation’s enrichment programs, and the broader ABA market provide multiple potential pathways for further deployment of Omni One in autism care.

“We are excited to move this initiative from research and development into real-world pilot programs with children,” said Jan Goetgeluk, Founder, Chairman and CEO of Virtuix. “Together with Rutgers University WINLAB, Sirica Therapeutics, and The LP Foundation, we are exploring how AI-driven, full-body immersive technology can help children practice important everyday life skills. If the pilot demonstrates clinical utility, we believe autism therapy could become a meaningful healthcare application for the Omni One platform.”

Rutgers University WINLAB has completed the first phase of its content development work, establishing a foundational framework and application for autism therapy using virtual reality and full-body movement on Omni One. The January pilot is expected to include five interactive virtual environments with different scenarios and levels designed to help children practice practical life skills, including crossing a street using traffic signals, finding an empty seat, navigating a supermarket aisle, and other everyday activities.

The initiative is part of Virtuix’s broader expansion into healthcare and rehabilitation. The Company recently sold Omni One systems to the U.S. Department of Veterans Affairs for deployment at a VA medical center in Detroit, Michigan, for potential applications including PTSD, anxiety, pain management, and occupational therapy. Virtuix is also collaborating with Florida Gulf Coast University’s Marieb College of Health & Human Services, where Omni One is being evaluated for applications including cognitive and neurological rehabilitation, physical and occupational therapy, and stroke rehabilitation.

These initiatives build on Virtuix’s strategy to expand Omni One beyond consumer entertainment and defense into healthcare applications where natural full-body movement inside immersive environments may provide new tools for therapy, rehabilitation, and clinical research.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.

Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.

About The LP Foundation

The LP Foundation is a nonprofit organization dedicated to creating stronger, healthier, and more inclusive communities. Its mission is centered around two equally important areas of impact: mental health and emotional wellness, and support, inclusion, education, and enrichment for individuals with intellectual and developmental disabilities, including autism and other forms of neurodiversity. The LP Foundation was founded by two sisters in honor of their late father and his lifelong legacy of compassion, generosity, and service. Inspired by his unwavering commitment to helping others, they transformed personal loss into purpose by building an organization rooted in the belief that every individual deserves dignity, opportunity, and a sense of belonging. For more information, visit https://thelpfoundation.com/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s sales and expansion plans, plans to pursue strategic acquisitions, potential impacts on future revenues or shareholder value, and the Company’s position in the defense training market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; risks related to government contracting, including contract cancellations, modifications, or funding changes; the uncertainties related to market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us

Both applications derive from a single optical approach designed to hold assembly complexity flat as channel counts rise; Company remains on track to show first demonstration hardware in January 2027

NEW YORK, NY, Sept. 23, 2026 (GLOBE NEWSWIRE) — Fabric.AI (Nasdaq: FABC) (“Fabric.AI” or the “Company”), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation AI factories, today announced that it has filed two patent applications with the United States Patent and Trademark Office (USPTO) covering its micro-LED optical interconnect architecture.

Both applications derive from the same design choice: imaging an entire micro-LED array through a novel optical system, rather than aligning light channel by channel. Through their partnership, Fabric.AI and Kopin Corporation (Nasdaq: KOPN) are jointly developing MicroLED-based optical interconnect technology designed to address bandwidth and energy-efficiency constraints in next-generation AI data centers.

Fiber-coupled: one optic, however many channels

The first application covers the Company’s approach to fiber-coupled optical interconnect, using a novel optical system to image an entire micro-LED array onto the cores of a multicore optical fiber. The architecture is designed to hold the number of precision alignment steps constant as channel count rises, rather than requiring alignment channel by channel.

Fabric.AI believes this is the property that allows dense parallel optical links — thousands of channels within a single square millimeter of die — to scale between boards, trays and racks without a corresponding rise in assembly cost.

Free-space: the same optic, without the fiber

The second application takes the same optical approach to its limit. Rather than imaging the array onto a fiber face, it transmits parallel data across a short air gap, eliminating the need for any physical connectors between the optical endpoints.

The technology uses compact optics to image the micro-LED array directly onto a matching detector array, holding the channels separate. Because the coupling is imaged rather than bonded, the fiber becomes optional: for short, fixed gaps inside a package or between adjacent boards, removing the connector removes both a failure point and an assembly step.

“Both applications come from one architectural choice: we image the whole array using special optics instead of aligning light channel by channel. That is what we believe keeps assembly complexity flat as we scale from hundreds of optical channels toward thousands — and what lets us remove the connector entirely where the gap is short enough,” said James Altucher, Fabric.AI Senior Strategic Advisor. “We continue to collaborate with Kopin in refining our technology and look forward to sharing these innovations in more detail with those potential customers currently under NDA discussions, as well as to providing more updates as they develop.”

These applications also underscore Fabric.AI’s continued collaboration with Kopin on Neural I/o™, its optical interconnect architecture designed to address the increasing data-movement, bandwidth and energy-efficiency demands of next-generation AI infrastructure. The Company expects to demonstrate working Neural I/o hardware in January 2027.

About Fabric.AI

Fabric.AI (Nasdaq: FABC) is an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation AI factories, including its Neural I/o ^TM MicroLED-based optical interconnect platform.

About Kopin Corporation

Kopin Corporation (Nasdaq: KOPN) is a leading developer and provider of innovative display and application-specific optical solutions for defense, AI infrastructure, enterprise, professional and consumer products. Kopin’s portfolio includes microdisplays, display modules, eyepieces and projection assemblies, and vehicle- and head-mounted display systems built on Kopin’s liquid crystal, MicroLED and OLED display technologies, along with a range of optics and low-power custom silicon. Building on its patented bi-directional NeuralDisplay™ architecture, Kopin is also developing Neural I/o optical interconnects that use programmable MicroLED pixels as ultra-high-speed, low-power optical transceivers for AI data centers. For more information, please visit Kopin’s website at www.kopin.com.

Follow Kopin on LinkedIn, X and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected timing, demonstration and capabilities of the Neural I/o ^TM platform. These statements are based on current expectations and are subject to risks and uncertainties — including development, integration and manufacturing risks — that could cause actual results to differ materially. Market and industry data are derived from third-party sources believed to be reliable but have not been independently verified by the Company. A discussion of these and other factors with respect to the Company is set forth in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

IR Contact:
CORE IR
212-644-0924
ir@fabric-ai.co

Media Contact:
Fabric.AI
press@fabric-ai.co
www.fabricai.com 

SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.

CardiAMP^® Autologous Cell Therapy for Ischemic Heart Failure

• BioCardia is working towards a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) in Q4 2026. The Company has recently provided detailed responses to PMDA consultation questions and is working with experienced partners on the Shonin Application, the Quality Management System Application, and Foreign Manufacturer Registration. PMDA support for the submission and a successful submission review could result in market clearance by Q4 2027.

• The confirmatory CardiAMP HF II clinical study is actively enrolling in the United States at four engaged world class centers. The Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) has indicated this study may support a Pre Marketing Application.

Helix™ Transendocardial Delivery Platform

• BioCardia intends to submit the follow-on De Novo pre-submission for the Helix Transendocardial Delivery Catheter System incorporating the FDA Center for Devices and Radiological Health (CDRH) this quarter. The FDA targets providing an initial acceptance/refusal review within 15 calendar days, and aims to issue written feedback or hold a meeting within 70 calendar days.

• An independent FDA clearance of Helix has the potential to expand BioCardia’s opportunities to partner with developers of investigational cell, gene and protein therapeutics requiring targeted delivery to the heart.

About BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph^® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information, visit www.biocardia.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to the timing and potential outcome of BioCardia’s regulatory submissions in Japan and the United States; the potential for the CardiAMP HF II trial to support Premarket Approval; submission for and subsequent market clearance of the Helix Transendocardial Delivery Catheter; business development and partnering opportunities; and the achievement of anticipated upcoming milestones.

These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release.

Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials and regulatory programs. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: 
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com 
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

THIS NOTICE IS NOT INTENDED, EXPRESSLY OR BY IMPLICATION, IN WHOLE OR IN PART, FOR DISTRIBUTION OR DISSEMINATION IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION, AND MAY NOT BE TRANSFERRED TO ANY JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION OF THIS NOTICE WOULD BE UNLAWFUL. CERTAIN OTHER RESTRICTIONS APPLY. PLEASE READ THE IMPORTANT DISCLAIMER BELOW IN THIS NOTICE TO THE SECURITY EXCHANGE.

AB ‘Civinity’ (the ‘Company’) has prepared a base prospectus for a programme of fixed-rate bonds with a maturity of up to 4 years and a nominal value of up to EUR 50,000,000 (ISIN LT0000134413) (the ‘Bonds’) for the issue and admission to trading on a regulated market of bonds with a nominal value of up to EUR 26,650,000 (the ‘Programme’) (the ‘Prospectus’), approved by the Bank of Lithuania on 23 September 2026.

Bonds with a value of EUR 23,350,000 under the same Programme and ISIN LT0000134413 have already been issued previously:

      (i)      Bonds with a value of EUR 10,350,000 were issued on 17 July 2025 pursuant to the exemption provided for in Article 1(4)(d) of Regulation (EU) 2017/1129 (the Prospectus Regulation) (an offer of securities addressed to investors who acquire securities for a total amount of not less than EUR 100,000 per investor);

      (ii)      Bonds with a value of EUR 13,000,000 were issued on 17 June 2026 in accordance with the prospectus dated 17 July 2025 for the issuance and admittance to trading on the regulated market of bonds with a total value not exceeding EUR 50,000,000, approved by the Bank of Lithuania on 18 July 2025.

The remaining amount of Bonds that may be issued and admitted to trading on the regulated market of AB ‘Nasdaq Vilnius’ pursuant to this Prospectus is EUR 26,650,000. All Bonds already issued under the Programme and those to be issued subsequently will be issued with a single ISIN code of LT0000134413 under the same Programme.

IMPORTANT NOTICE:

Legislation in certain jurisdictions may restrict the right to distribute this announcement and other information relating to securities. Persons who receive this announcement or other relevant information must familiarise themselves with and comply with such restrictions. This announcement is not intended for distribution to news agencies in the United States or for dissemination in the United States or in any other jurisdiction where such dissemination is not permitted. Furthermore, the securities referred to in this notice have not been and will not be registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States or to persons in the United States, unless such securities are registered under the Securities Act or an exemption from the registration requirements of the Securities Act is obtained. No public offering of securities will be made in the United States of America.

This notice does not constitute an offer or a solicitation to sell or to purchase securities or investments in any jurisdiction where such an offer or solicitation would be unlawful. The Prospectus is the only legally binding document containing information about the Company, the Bonds and their admission to trading on a regulated market. The Prospectus is published on the Company’s website at https://www.civinity.com/lt/investuotojams/, as well as at www.nasdaqbaltic.com.

The approval of the Prospectus should not be regarded as an endorsement of the quality of the Bonds to be admitted to trading on a regulated market. Prospective investors are advised to read the Prospectus before making an investment decision so that they understand all the potential risks and returns associated with the decision to invest in the Bonds.

Person responsible for the publication of information:

Darius Alutis

Head of the Legal Department at AB “Civinity”

Email: darius.alutis@civinity.com

Mobile: +370 613 06099

Attachments

• LB Sprendimas_Civinity_2026_428-75
• Prospectus_retail_(Civinity) (2026_09_22)(FINAL)